SCHEMBL24286644

SCHEMBL24286644

Nc1nc2c(F)cc(-c3cccc4[nH]ccc34)cn2c1C(=O)[C@@H]1C[C@@H]1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 7/20 0.36
▸ PIK3CD O00329 5/20 0.35
▸ PIK3CB P42338 4/20 0.35
▸ PIK3CG P48736 2/20 0.35
▸ EGFR P00533 1/20 0.35
▸ HCK P08631 1/20 0.35
▸ SRC P12931 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ MTOR P42345 1/20 0.35
▸ EPHB4 P54760 1/20 0.35
▸ PRKDC P78527 1/20 0.35
▸ PI4KB Q9UBF8 1/20 0.35
▸ ASH1L Q9NR48 1/20 0.35
▸ LRRK2 Q5S007 4/20 0.35
▸ GSK3B P49841 2/20 0.35
▸ PIM1 P11309 1/20 0.35
▸ MAP4K1 Q92918 1/20 0.34
▸ PRKCA P17252 1/20 0.34
▸ FLT3 P36888 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29536925 1.00 ABL1 (0.36) ABL1PIK3CDPIK3CBPIK3CGEGFR
SCHEMBL24286642 0.89 LRRK2 (0.38) ABL1PIK3CDPIK3CBLRRK2GSK3B
SCHEMBL29537790 0.84 MAP4K1 (0.43) ABL1PIK3CDPIK3CBLRRK2MAP4K1
SCHEMBL24285857 0.84 MAP4K1 (0.43) ABL1PIK3CDPIK3CBLRRK2MAP4K1
SCHEMBL24286626 0.83 LRRK2 (0.37) ABL1PIK3CDPIK3CBPIK3CGEGFR
SCHEMBL29537733 0.83 LRRK2 (0.37) ABL1PIK3CDPIK3CBPIK3CGEGFR
SCHEMBL24285952 0.82 LRRK2 (0.51) ABL1LRRK2
SCHEMBL29537853 0.81 ABL1 (0.37) ABL1PIK3CALRRK2MAP4K1FLT3
SCHEMBL24286211 0.81 ABL1 (0.37) ABL1PIK3CALRRK2MAP4K1FLT3
SCHEMBL24285946 0.76 LRRK2 (0.37) ABL1LRRK2MAP4K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4214207-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1st Biotherapeutics, Inc. (KR) 2023-07-26 — — EP claimed
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1ST Biotherapeutics, Inc. (KR) 2022-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds NLRP3, NLRP1, KCNJ2 ABL1 966/4885PIK3CD 923/4885PIK3CB 1320/4885
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS NLRP3, NLRP1, KCNJ2 ABL1 966/4885PIK3CD 923/4885PIK3CB 1320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback